Opportunity ID: 308638

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DK-18-504
Funding Opportunity Title: Limited Competition for the Continuation of Cure Glomerulonephropathy (CureGN) Data Coordinating Center (U24 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Aug 30, 2018
Last Updated Date:
Original Closing Date for Applications: Nov 21, 2018
Current Closing Date for Applications: Nov 21, 2018
Archive Date: Dec 27, 2018
Estimated Total Program Funding:
Award Ceiling: $1,000,000
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see the funding opportunity for eligibility details

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Limited Competition is to extend the Cure Glomerulonephropathy (CureGN) Network by continuing to support the Data Coordinating Center (DCC). The CureGN Network is a multicenter observational cohort study of glomerular disease patients with the goal of improving care for all glomerular disease patients. The operational components of the study include four multi-site Participating Clinical Centers (PCC) and a DCC. The CureGN Network, established in 2013, has recruited nearly 2,200 of 2,400 planned study participants and followed them with annual in-person clinic visits and interim telephone contacts. The DCC provides key leadership functions for this study in the areas of study organization, study design and implementation, overall management, data management and analysis, and biosample management. The CureGN PCCs will continue to follow-up previously enrolled participants under a separate FOA with a focus on clinical assessment of disease activity, developing novel methods for “virtual” study participation,and semi-quantitative assessment of histopathologic lesions. It is expected that a focus on disease features unique to glomerulonephropathy and outcomes relevant to the full range of patient experience, combined with carefully curated clinical and biochemical data, will uncover new predictors of the disease course, pathophysiologic processes, disease subtypes and novel treatment targets. The DCC will lead the study group to achieve the scientific goals of the next project period.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-504.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-E FORMS-E PKG00244705 Oct 21, 2018 Nov 21, 2018 View

Package 1

Mandatory forms

308638 RR_SF424_2_0-2.0.pdf

308638 PHS398_CoverPageSupplement_4_0-4.0.pdf

308638 RR_OtherProjectInfo_1_4-1.4.pdf

308638 PerformanceSite_2_0-2.0.pdf

308638 RR_KeyPersonExpanded_2_0-2.0.pdf

308638 RR_Budget_1_4-1.4.pdf

308638 PHS398_ResearchPlan_4_0-4.0.pdf

Optional forms

308638 RR_SubawardBudget30_1_4-1.4.pdf

308638 PHS_AssignmentRequestForm_2_0-2.0.pdf

2025-07-09T21:04:48-05:00

Share This Post, Choose Your Platform!

About the Author: